Connect
Mosunetuzumab plus polatuzumab vedotin (BiTE) therapy for DLBCL
Because of age and prior treatments my wife’s lymphoma in pelvic area and breast was treated with Pola-R ; not the standard treatment.
However the PET Scan after 4 cycles showed only partial response. Whereas the pelvic area reacted well and eating and digestion is back to normal the breast mass shows partial response only.
The hospital now started a Polatuzumap plus Monsunetuzumap(bite)treatment.
Any experience to share about breast mass behavior during treatment? Like mass shrinking early and it can be measured by tape or no measurable shrinking because of necrosis-dead cells ?
Like
Helpful
HugInterested in more discussions like this? Go to the Blood Cancers & Disorders Support Group.
Connect
@kippi1950, I had to look up the treatment that your wife will be starting. What I learned is that mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) is a promising combination therapy for aggressive B-cell lymphomas, such as relapsed or refractory Large B-cell Lymphoma (LBCL). It pairs a targeted bispecific T-cell engager (BiTE) with an antibody-drug conjugate (ADC) to selectively destroy cancer cells.
- FDA Accepts sBLA for Subcutaneous Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL https://www.onclive.com/view/fda-accepts-sbla-for-subcutaneous-mosunetuzumab-plus-polatuzumab-vedotin-in-r-r-lbcl
Is your wife on a clinical trial? How is she doing?
They are following a clinical trial protocol including dosage escalation to reduce the risk of cytokines release syndrome. She is treated as outpatient and now gets infusions every 3 weeks.
She had experienced severe weight loss in a short period of time because the lymphoma had spread in the digestion tract in a short period of time. With Pola-R she regained weight and was back to baseline but the response as per PET Scan was not complete hence the change to or addition of monsunetuzumap. She now visits restaurants and concerts.
It is not fully understood why her lymphoma in the pelvic /abdominal area reacted well and her lymphoma breast mass showed only partial response. The tumor biology may be different; clonal aspects ?
The next PET Scan is planned for mid August. The difficulty now: the breast mass may react to new treatments but it cannot be felt or measured because of necrosis. You can’t tell the difference between dead cells and active lymphoma.